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Introduction
Hepatitis C virus (HCV) is considered to represent the
principal causative agent of chronic hepatitis, cirrho-
sis and hepatocellular carcinoma (HCC). The search
continues for reliable (serum and tissue) markers of
progression manifested by HCV-related chronic hepa-
titis to hepatocellular carcinoma [1,2]. A disturbed
cell-cycle control is a HCC risk factor in patients with
HCV-related liver damage [3]. Results of studies indi-
cate alterations in expression of cell-cycle-linked pro-
teins with the block in hepatocyte cell cycle in G1
phase [4,5]. An experimental proof is available for the
role of three HCV proteins: the core protein, non-
structural protein 3 (NS3), and NS5A in control of the
cell cycle [6]. The most important host proteins which
control cell cycle are thought to include the wild-type
p53 and p21 proteins [7]. The p21/Wafl/Cipl (p21) pro-
tein is a downstream target effector of wild-type p53
[8]. The best recognised role of p21 involves inhibi-
tion of cyclin complexes (CKI) with numerous cyclin-
dependent kinases: CDK4/D, CDK6/D and CDK2/E,
which control introduction of the cell to the cycle and
start of DNA replication [9]. p21 co-localizes and
FOLIA HISTOCHEMICA
ET CYTOBIOLOGICA
Vol. 47, No. 3, 2009
pp. 385-394
p21/Wafl/Cipl cellular expression in chronic long-lasting
hepatitis C: correlation with HCV proteins 
(C, NS3, NS5A), other cell-cycle related proteins 
and selected clinical data
Aldona Kasprzak1, Agnieszka Adamek2, Wies³awa Przybyszewska1, 
Karolina Olejniczak1, Wies³awa Biczysko3, Iwona Mozer-Lisewska2, Maciej Zabel1
1Department of Histology and Embryology, University of Medical Sciences, Poznañ;
2Department of Infectious Diseases, University of Medical Sciences, Poznañ;
3Department of Clinical Pathomorphology, University of Medical Sciences, Poznañ, Poland
Abstract: Studies indicate that proteins of hepatitis C virus (HCV) disturb expression of cell-cycle-related proteins. A dis-
turbed cell-cycle control is a hepatocellular carcinoma (HCC) risk factor in patients with HCV-related liver damage. The
present study aimed to analyse the cellular expression of p21/Wafl/Cipl (p21) in long-lasting chronic hepatitis C (CH-C), its
correlation with the key oncogenic HCV proteins (C, NS3, NS5A), other cell-cycle-related proteins (PCNA, Ki-67, cyclin
D1, p53) and selected clinical data. Archival liver biopsies, obtained from patients with CH-C, normal livers, and hepato-
cellular carcinoma (HCC) specimens were analysed by immunocytochemistry and ImmunoMax technique. In CH-C over-
expression of p21 protein was demonstrated. Positive correlations of p21 protein expression in CH-C involved age of the
patients, grading, and liver steatosis. Moreover, expression of p21 correlated significantly with expression of p53 protein,
of D1 cyclin and Ki-67. Although Ki-67 antigen was related to p21 expression, only Ki-67 expression proved to be direct-
ly related to liver staging. Expression of the NS3 protein, which prevailed in CH-C patients, manifested correlation with p21
expression, and that of cyclin D1. In presence of preserved potential for regeneration, overexpression of p21 indicates inhi-
bition of cell cycle in hepatocytes, which probably plays a protective role for the chronically damaged cells. Out of the three
HCV proteins only NS3 seems to affect control of p21 protein expression in in vivo infection. Nevertheless, the studies indi-
cate that neither expression of p21 protein nor that of viral NS3 protein can serve as a marker of progression of CH-C to
HCC in vivo. 
Key words: Long-lasting chronic hepatitis C, p21/Wafl/Cipl and other cell cycle-related proteins, NS3, NS5A and C protein,
ABC and ImmunoMax methods
Correspondence: A. Kasprzak, Dept. of Histology and 
Embryology, Poznan University of Medical Sciences, 
Œwiêcickiego Str 6, 60-781 Poznañ, Poland; 
tel.: (+4861) 8546441; fax: (+4861) 8546440, 
e-mail: akasprza@ump.edu.pl
binds also with the proliferating cell nuclear antigen
(PCNA) [10] and it may directly inhibit PCNA-
dependent DNA replication [11]. In response to mito-
gens, p21 is induced during G1 phase and, thus,
appears to perform a role in normal cell cycle pro-
gression in the absence of growth inhibitors [12]. p21
protein was also shown to block cell cycle in G2
phase, which is dependent on retinoblastoma protein
[13]. In tissue culture systems, p21 is up-regulated in
proliferating cells [12], whereas, in other cell types, it
is induced during senescence and terminal differenti-
ation, and it is thought to play a key role in down-reg-
ulating CDK activity in these settings [14]. The p53-
dependent expression of p21 plays a central role in
cell growth regulation and apoptosis [8]. p21 can be
induced also in a p53-independent manner [12,13]. In
normal tissue expression of p21 to high levels is not
dependent on p53 and confirms that induction of p21
by DNA-damaging agents does require p53 [12]. 
In cases of chronic hepatitis C (CH-C) more p21-
immunopositive cells were demonstrated in cirrhotic
lesions of the liver as compared to regions with
inflammatory lesions [2]. The other studies in HCV
infection point to correlation between p21 expression
and fibrosis stage, grading and serum HCV RNA lev-
els and they document block in cell cycle in G1 phase
[4]. In HCC a decreased expression of p21 was
detected mainly as result of a mutation of p53
[15,16]. Recent studies indicate also that prolifera-
tion of human HCC cells requires JNK1-dependent
p21 downregulation [17]. Evaluation of p21 expres-
sion is also of importance in distinguishing patients
with a risk of a more rapid progression from chronic
hepatitis to HCC [1].
The in vitro studies on interactions between HCV
proteins and p53 and/or p21 genes provide variable
results. The most numerous interactions were docu-
mented for the HCV core protein (capsid, C protein)
[18-21]. The originally incompatible results of stud-
ies on stimulation of p21 expression by the core pro-
tein [20,21] or on inhibition of the expression [22],
seemed to be explained by the subsequent papers.
The effects of interactions with p53 and/or p21 were
found to be dependent both upon the concentration of
the core protein and on its localization in the cell
[19,23]: low concentration of the core protein stimu-
lated activity of p53 while its high concentration
decreased the activity [19]. The cytoplasmic form of
core protein augmented p21 expression (via activa-
tion of p53) and the mature form in the cell nucleus
inhibited it (the p53-independent pathway) [23]. In
an another study inhibition of p21 synthesis was
demonstrated by the core protein situated in the cyto-
plasm [24]. Out of the non-structural HCV proteins,
NS3 can promote growth [25] but NS5A protein can
either promote [26] or inhibit growth via up-regula-
tion of p21 [27]. Few in vivo studies are available
which attempted to correlate cellular expression of
p21 and p53 protein expression in CH-C with expres-
sion of the potentially oncogenic HCV proteins [28].
Moreover, the literature data are inconsistent as to the
tissue expression of cell cycle-related proteins and
the relationships between clinical data and tissue
expression of HCV proteins in vivo. Examining
effects of active HCV replication on alterations in
cell cycle proteins of the host cells in vivo, we
attempted to find out if cellular expression of
p21/Wafl/Cipl protein correlates with expression of
potentially oncogenic HCV proteins (C, NS3, NS5A)
and with clinical data in long-lasting chronic hepati-
tis C. We undertook an attempt to examine the rela-
tionship between expression of HCV proteins and
expression of the typical proliferation-associated
antigens, i.e., Ki-67 and PCNA (present in all phases
of cell division), cyclin D1 (engaged in control in
phases G1-S of the cell cycle) and p53 protein, which
controls proliferation of normal cells, DNA repair
and apoptosis. We aimed also to assess the potential
relationship between cellular expression of the cell-
cycle proteins and selected clinical data in long last-
ing CH-C (mean duration of HCV infection approxi-
mately 20 years). 
Material and methods
Liver samples. Studies were performed on 29 archival biopsies of
liver, obtained from adult patients (16 men and 13 women) with
documented chronic, long-lasting hepatitis C and with active repli-
cation of the virus, confirmed serologically (all the patients were
anti-HCV and HCV RNA positive). The biopsies originated from
patients of the Department of Infectious Diseases Poznan Univer-
sity of Medical Sciences, in whom the biopsies were performed in
2005-2008. All the patients were seronegative for both HBsAg and
HBeAg, and for IgM antibody against cytomegalovirus (CMV),
against Epstein-Barr virus (EBV) and against HIV-1 and HIV-2 by
standard enzyme immunoassays (ELISA). Other cases of liver
damage (e.g. α1-antitrypsin deficiency, Wilson's disease, alcohol
dependency) were ruled out. All the patients had exhibited elevat-
ed serum alanine transaminase level (normal level below 40 IU/l)
for at least 6 months. All the patients were seropositive for anti-
body to HCV by ELISA (HCV version 3.0 AXYM System,
Abbott). Quantitation of HCV RNA was conducted using
AMPLICOR HCVTM test, version 2.0 (ROCHE, Mannheim, Ger-
many) with sensitivity of 600 IU/ml. The test was standardized
against the WHO International Standard for HCV RNA. Before
liver biopsy none of the patients was subjected to anti-viral thera-
py. The duration time of the infection was estimated basing exclu-
sively on the infection factor HCV (blood transfusion, extensive
operation, long hospitalization). Written informed consent was
obtained from each patient before liver biopsy, and approval for the
study was granted by the institution's Ethical Committee. 
The negative control samples were obtained from livers of
serologically HCV-, HBV-, HCMV- and EBV-negative organ
donors and normal livers from tissue microarray panel (Cybrdi
Inc.; Maryland, USA) (n=13). These normal controls were without
morphological evidence of pathology. Appropriate positive control
for cell cycle-related protein expression involved the livers with
HCC from patients and tissue microarray panel (Cybrdi Inc.)
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(n=18). Only one patient from HCC group was HCV-positive, in
the remaining patients their serological status related to HCV
infection remained unknown.
Liver biopsy specimens fixed in 10% buffered formalin,
embedded in paraffin were evaluated histologically by two experi-
enced histopathologists (WB and JB), following the H+E staining
as well as silver technique and tri-chromate technique, according to
Masson and periodic acid-Schiff with diastase pretreatment. At
least 10 sections were prepared from each biopsy or from control
livers. Each tissue specimen was evaluated basing on a numerical
scoring system for the grade of portal/periportal necroinflamma-
tion (G1=0-4), for the grade of lobular necroinflammation (G2=0-
4) and for the stage of fibrosis (S=0-4) [29]. 
Immunocytochemistry. For immunocytochemistry 5 μm thick sec-
tions were cut and mounted onto SuperFrost/Plus microscope slides.
Mouse anti-human monoclonal antibodies were employed, directed
against (1) the p21Wafl/Cipl protein (clone SX118; DAKO, Glostrup,
Denmark; in 1:50 dilution), (2) the human Ki-67 antigen (clone
MIB-1) (DAKO, 1:2), (3) the PCNA antigen (DAKO, 1:200), (4)
cyclin-D1 (clone: DCS-6; DAKO; ready-to-use dilution), (5) the p53
protein (clone DO-7; DAKO; ready-to-use), (6) capsid C protein
(CHEMICON International, Inc., 1:50), (7) NS3 protein and (8)
NS5A protein (both from NOVOCASTRA Labs., 1:50). The studies
followed the ABC technique and/or the ImmunoMax technique (in
case of p21, NS3, NS5A, C proteins) as described earlier [30,31]. In
ImmunoMax technique, the key reaction involved 8 min incubation
with biotinylated tyramine (PerkinElmer Life Sciences, Inc., 1:50) at
room temperature. Control reactions were based on substituting spe-
cific antibodies with normal sera of the respective species in 0.05 M
Tris-HCl, pH 7.6, supplemented with 0.1% BSA and 15 mM sodium
azide (internal negative control). 
Semiquantitative evaluation of the results. The frequencies of
staining and the contents of HCV proteins, p21, Ki-67 and PCNA
antigens, cyclin D1, and p53 protein in liver biopsies obtained
using ABC and/or ImmunoMax technique were independently
measures by two investigators. The interobserver and intraobserv-
er variation was <10%. Expression of HCV proteins and cell cycle-
related proteins (cell nuclei and/or cytoplasm of hepatocytes) was
calculated taking into account mean proportion of immunopositive
cells in 10 different areas of each specimen. Positive nuclear or
cytoplasmic staining was evaluated by counting a total of at least
1000 cells. Steatosis of liver was also semiquantitatively appraised,
scoring 0 when no steatosis was noted under a light microscope,
and annotating grades 1 or 2 when, respectively, <30% of hepato-
cytes or 30-70% of hepatocytes were affected [32]. Alphafetopro-
tein (AFP) expression in hepatocytes were calculated and reported
as follows: 0=0% positive cells; 1=individual positive cells
(<10%); 2=10-25% positive cells; 3=26-50% positive cells; 
4=51-75% positive cells; 5=76-100% positive cells) [33], evaluat-
ing 10 microscopic fields at magnification of 400×. The final result
represented mean score for the 10 fields. All the preparations were
examined under an OLYMPUS B-2 light microscope. 
Statistical analysis. The descriptive statistics included calculation
of mean, median values, standard deviation and standard error of
the mean (SEM) for quantitative traits. In order to determine sta-
tistical significance of variations in the expression of the proteins,
we first calculated the mean values of staining scores for liver
biopsy groups. In comparison of quantitative traits the Mann-
Whitney's U test was used for non-parametric independent data.
Correlations between data rows were determined employing
Spearman's rank correlation index and Kruskal-Wallis test. Proba-
bility values less than 0.05 were considered significant.
Results
At the time of biopsy the mean age of patients (16 men
and 13 women) was 42±3 years (range: 19 to 74 years)
and the mean duration of HCV infection was 20.9±2.1
years. The majority (76%) of the patients included in
our study were infected by HCV genotype 1b. Epi-
demiological, biochemical and virological data of
patients are summed up in Table 1.
Liver grading, staging and steatosis in HCV-
infected patients. 
Mean values of grading, staging, steatosis of liver and
AFP expression in tissue are listed in Table 1. A statis-
tically significant positive Spearman's correlation was
documented between grade of portal/periportal
necroinflammatory (G1) (r=0.369; p=0.048) (data not
shown) and total grading (G1+G2) on one hand and
steatosis on the other (r=0.362; p=0.05), between total
grading on one hand and staging on the other
(r=0.725; p=0.001) (Fig. 1). 
Expression of HCV proteins (C, NS3 and
NS5A)
Cytoplasmic expression of all the three HCV proteins
prevailed. Nuclear localization of C, NS3 and NS5A
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Table 1. Epidemiological, histological and clinical data of the patients with chronic long-lasting hepatitis C.
Legend: Values shown mean value and standard error of the mean (SEM); y – years; * – histopathological scoring (see section:  Materials and methods); G1 – grade of por-
tal/periportal necroinflammatory; G2 – grade of lobular necroinflammation; S – stage of fibrosis; AFP – alphafetoprotein
was observed only in individual cells (Fig. 2). A statis-
tically significant most pronounced expression in
hepatocytes pertained the NS3 protein, both as com-
pared to C protein and NS5A. No quantitative differ-
ences were disclosed in expression of C protein and
NS5A protein (Table 2). A positive Spearman's corre-
lation was documented between expression of NS3
protein and NS5A protein in livers of HCV-positive
patients (r=0.428; p=0.03) (data not shown). In the
negative control no HCV protein expression was
detected. In HCC expression of HCV proteins was
noted in only one patient (Table 2 and Fig. 2).
Expression of cell cycle-related proteins
Expression of p21/Wafl/Cipl. Expression of p21 protein
was detected in 22/25 (88%) of the examined liver
samples; the immunocytochemical reaction used to be
markedly intense and present exclusively in cell nuclei
(Fig. 3). On the average, the expression was observed
in 23.6±4.1% cells (Table 2). It was significantly high-
er than expression of the protein in both controls
(p=0.0001) and higher than expression of p53 protein
(p=0.0001). A positive, statistically significant Spear-
man's correlation was disclosed between expression of
p21 and that of p53 (r=0.397; p=0.049), between
expression of p21 and Ki-67 (r=0.437, p=0.03), and
also between expression of p21 and that of cyclin D1
(r=0.532; p=0.007) (Fig. 4). Moreover, the expression
of p21 protein demonstrated correlation both with total
grading (G1+G2), and with liver steatosis (r=0.413;
p=0.04; r=0.452; p=0.02, respectively) (Fig. 5). In the
negative control no p21 expression was noted. In HCC
both nuclear and cytoplasmic positive reaction for p21
was observed rather in individual cells and only in
4/18 examined tumours (Fig. 3). The average percent-
age of the expression amounted to 1.2±0.6 cells (Table
2). It was significantly lower than the expression noted
in hepatitis C (p=0.001). No significant differences
were seen between expression of p21 in the negative
control and in HCC (p=0.298). 
Expression of p53 protein. As a rule p53 protein was
detected in cell nuclei although individual cells were
detected with the cytoplasmic reaction (Fig. 3). The
average expression of p53 involved less than 10% cells
(Table 2). A positive Spearman's correlation was
observed between expression of p53 and p21 in HCV-
infected patients (r=0.397; p=0.049) (Fig. 4). Expres-
sion of p53 failed to correlate with grading, staging,
and/or steatosis. In the negative control no expression of
p53 protein was noted. In HCC numerous p53-positive
cells were observed in a few patients (Fig. 3). In HCC
the average expression of p53 amounted to 16.8±5.6%
cells and even if the result was higher than that in CH-
C patients, the difference proved to be insignificant
(p=0.06). On the other hand, a significantly higher p53
expression was detected in HCC group, as compared to
the negative control (p=0.004) (Table 2).
Expression of Ki-67, PCNA and cyclin D1. Expres-
sion of Ki-67, PCNA and cyclin D1 was seen exclu-
sively in cell nuclei. The frequency of PCNA manifes-
tation in liver biopsies amounted to 92% patients and
on the average expression of the antigen could be seen
in 12.6±2.4% cells. Ki-67 was demonstrated in all
liver biopsies in the mean proportion of 10.2±1.8%
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Table 2. Expression of HCV proteins and of p21/Wafl/Cipl (p21) pro-
tein and the remaining cell-cycle linked proteins in patients with
chronic hepatitis C (CH-C), negative control (CONTR.) and posi-
tive control (hepatocellular carcinoma, HCC). The numbers indi-
cate mean percentages and standard error of the mean (SEM).
Legend: a – p=0.001 NS3 vs. C and NS5A in CH-C; b – p=0.0001 p21 
vs. p53;  c – p=0.004 cyclin D1 vs. PCNA; d – p=0.002 cyclin D1 vs. Ki-
67;  * – p=0.0001 p21 in CH-C vs. HCC; ** – p=0.002 PCNA in CH-C vs.
HCC; *** – p=0.004 Ki-67 antigen in CH-C vs HCC; NS – statistically non
significant between the respective groups
Fig. 1. Spearman's correlation between the total liver grading
(G1+G2) and for the stage of liver fibrosis (staging) and liver
steatosis.
cells. In the group of patients no significant differences
could be detected in cellular expressions of PCNA and
Ki-67. However, as compared to the negative control,
the expression was higher in CH-C patients (Table 2).
Expression of cyclin D1 was noted, on the average, in
4.4±1.1% of studied cell nuclei in 11/24 (46%) liver
biopsies (Table 2). Expression of cyclin D1 was sig-
nificantly lower than expression of PCNA (p=0.004)
or Ki-67 antigen (p=0.002). In the case of Ki-67 the
more intense immunocytochemical reaction was
observed as compared to those detecting PCNA and
cyclin D1 (Fig. 3). No significant reciprocal correla-
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Fig. 2. Micrographs of normal livers (CONTR.), chronic hepatitis C (CH-C), and hepatocellular carcinoma (HCC). First panel (left) shows
hematoxylin/eosin (HE)-stained sections to demonstrate normal histology (CONTR.), characteristic enlarged hepatocytes with swollen,
partially vacuolised cytoplasm, often with the evident fatty degeneration in chronic hepatitis C (CH-C) and acinar/pseudoglandular pat-
tern and nuclear crowding in hepatocellular carcinoma (HCC). The next panels show immunocytochemical staining for HCV proteins: 
C (core), NS3 and NS5A. Original magn. ×400.
Fig. 3. Micrographs of normal livers (CONTR.), chronic hepatitis C (CH-C), and hepatocellular carcinoma (HCC). Panels show immuno-
cytochemical staining for cell-cycle related proteins: p21WAF-1/CIP-1, p53, PCNA, Ki-67 antigen and cyclin D1. Original magn. ×400.
tions could be documented between expressions of
proliferation-associated antigens. Significant positive
correlations were detected between expression of the
Ki-67 antigen and grading, both in portal spaces (G1)
(r=574; p=0.002), and in the lobules (G2) (r=0.517;
p=0.008), and total grading (G1+G2) (r=0.618;
p=0.001). Expression of Ki-67 proved to be directly
related to steatosis of the liver (r=0.489; p=0.01) (Fig.
6) and to the staging (test of Kruskal-Wallis, p=0.046)
(Fig. 7). In the negative control only individual Ki-67-
positive or PCNA-positive cells were noted, as com-
pared to numerous Ki-67-positive and PCNA-positive
in HCC (Fig. 3). A significantly higher expression of
both proliferation markers was noted in HCC, as com-
pared to CH-C and control (Table 2). In the case of
cyclin D1 individual cells with expression of the pro-
tein were observed in the negative control material
while in HCC expression of the protein was observed
in relatively numerous cell nuclei (on the average in
10.6±3.4% of the cells) (Fig. 3). In HCC expression of
the protein was higher than in patients with CH-C and
than in the negative control but the difference was sta-
tistically insignificant (Table 2). 
Correlations between HCV proteins and pro-
teins of the cell cycle
Expression of the NS3 protein manifested significant
correlation with expression intensity of both p21
(r=0.399; p=0.048), and that of cyclin D1 (r=0.455;
p=0.02) (Fig. 8). No correlation could be noted
between expressions of HCV proteins and Ki-67 anti-
gen, PCNA and p53. 
Correlations between studied cell cycle markers,
HCV proteins and clinical data 
None of the studied HCV proteins manifested correla-
tion with patient's age, duration of HCV infection,
serum levels of HCV RNA and AFP or tissue AFP
expression. Out of cell cycle proteins only expression
of p21 manifested a direct relationship to patient's age
(r=0.449; p=0.02). The remaining cell cycle proteins
demonstrated no significant correlations with the clin-
ical data. 
Discussion
Most frequently, the oncogenic properties of HCV pro-
teins are linked to their potential for translocation to
cell nucleus and to the control of cell cycle through
their cooperation with cell-cycle related proteins and
to control of apoptosis. Several studies point to the
relationship between subcellular localization of HCV
proteins, their levels, specific molecular form, pres-
ence of specific domains and their effect on oncogen-
esis-linked mechanisms [6]. The search continues for
reliable (serum and tissue) markers of progression
manifested by HCV-related chronic hepatitis to hepa-
tocellular carcinoma [1,2]. 
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Fig. 4. Spearman's correlation between expression of p21 protein
and of Ki-67 antigen, p53 protein and cyclin D1 cellular expres-
sion.
Fig. 5. Spearman's correlation between expression of p21 and of
the total grading (G1+G2) and for the liver steatosis.
Fig. 6. Spearman's correlation between expression of Ki-67 anti-
gen and of portal/periportal necroinflammation (G1), the grade of
lobular necroinflammation (G2), total grading (G1+G2) and for
the liver steatosis.
Present studies have demonstrated mostly cytoplas-
mic expression of all three viral proteins (C, NS3 and
NS5A) in patients with CH-C, which is consistent with
the earlier observations [32] and with the currently
accepted knowledge on HCV replication [3]. Expres-
sion of NS3 protein has prevailed. In the currently
examined group of patients similarly to the earlier stud-
ies [32] no correlation could have been detected
between expression of HCV proteins and histological
lesions or selected clinical variables. This remains in
agreement with results of other authors [28]. On the
other hand, we have noted that expression of NS3 pro-
tein was directly related to expressions of p21 and
cyclin D1. We have not been able to confirm the in 
vitro results demonstrating positive [20,21] or negative
relationships [22,24] between core protein and p21 pro-
tein. We also couldn't demonstrate any correlation
between NS5A protein and p21 protein expression
[26,27]. Similarly to our results, a strong positive cor-
relation between NS3 and p21 in non-neoplastic HCV-
positive lesions adhering to HCC has been demonstrat-
ed by few authors [28]. In general, NS3 is known to be
linked to the neoplastic transformation of normal hepa-
tocytes in chronically infected patients [6]. In in vitro
experiments it was demonstrated that NS3 specifically
inhibited activity of p21/WAF1 promoter, especially
when combined with HCV core protein [25]. In turn,
studies of other authors point to an inhibitory effect of
various HCV proteins (e.g. core protein), but not NS3,
NS5A or NS5B on expression of p21 at the translation
level [34]. Thus, the effect of NS3 protein on cell cycle-
related proteins (including p21) in HCV-infected cells
does not always involve inhibition and the effect prob-
ably depends upon reciprocal co-operation of all HCV
proteins. In present study we have corroborated the
positive correlation between expression of p53 and
p21, similarly to the results of some authors obtained in
HCV infection [28]. In our HCV-positive material p21
has been the most frequently manifested cell cycle pro-
tein (24%). Our observations indicate that if expression
of p21 was so frequent, the hepatocytes contained func-
tional wild-type p53 protein. We can confirm the earli-
er data that the p53-dependent mechanism of p21
expression is observed more frequently as a result of
DNA damage, e.g., due to infection with HCV, than due
to the p53-independent mechanism in "normal cells"
[12]. Nevertheless, the augmented expression of p21
together with increased production of nitric oxide syn-
thase (NOS-2) without parallel detection of p53 was
detected in chronic hepatitis C [35]. In HCV infection
subsequent authors demonstrated also elevated expres-
sion of p21 and p53 proteins, but without reciprocal
correlations [5]. Studies of still other authors proved
that expression of the protein may represent an inde-
pendent prognostic index of HCC development in
humans [2]. In our patients with CH-C, expression of
p21 has been directly related to expression of Ki-67
antigen, similar to other authors [36]. Similarly to the
latter authors we have not been able to demonstrate
expression of p21 in "normal" livers [36]. In liver biop-
sies with a particularly intense expression of p21 and
Ki-67, up-regulation of p21 may reflect simply
increased numbers of proliferating cells, which is
observed during progression of hepatic diseases and in
liver regeneration [1,5,12,36]. Positive correlation
between the p21/MIB-1 coefficient and number of dys-
plastic lesions was demonstrated in patients with high-
ly advanced chronic hepatitis of various etiology
(including HCV infection) [1]. Other studies indicate
that positive correlations between p21 expression and
end-stage liver disease scoring point to inhibition of
hepatocyte proliferation in the course of evolution of
chronic hepatitis to liver cirrhosis and that this is
accompanied by up-regulation of p21 [37]. Even if
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Fig. 7. Comparison of Ki-67 antigen expression with respect to
liver fibrosis score (staging) (test of Kruskal-Wallis).
Fig. 8. Spearman's correlation between expression of NS3 protein
and p21 and cyclin D1 cellular expression.
other authors also observed a correlation between p21
and staging in CH-C, in the same study they detected
positive correlation between the proliferation marker,
Mcm-2 and staging [5]. In the material studied by us
expression of p21 has manifested correlation with
grading and with steatosis of liver but not with stag-
ing. Similarly to other authors we have noted positive
correlation between staging and expression of Ki-67
[5]. This indicates at least a partially preserved poten-
tial of hepatocytes for regeneration in long-lasting
CH-C. On the other hand, however, chronic hepatitis
and increased proliferation of hepatocytes may pro-
mote development of HCC. The examined by us
patients have demonstrated a low expression of Ki-67
(10%), and histopathological evaluation of cirrhosis
has pertained 10/29 (34%) patients. In the HCC group
expression of p21 has been low as a rule, accompa-
nied by variable expression of p53 positivity in livers
of patients with HCC, which points to the lowered
production of p21 in this type of human tumours. The
result corroborates conclusions of other authors
[16,28]. However, except of a single case, we cannot
specify etiology of HCC in our material. Other stud-
ies on patients with CH-C documented positive rela-
tionship between staging and accumulation of
replicative senescent cells, evaluated by estimation of
activity shown by senescence-associated beta galac-
tosidase [38]. In our studies expression of p21 corre-
lated also with age of the patients, which seems to
confirm the observations that senescent cells in liver
in vivo are associated with older age [38]. As men-
tioned above, we have not been able to demonstrate
relationships between expression of p21 and staging
[2,37], probably due to the relatively low number of
liver cirrhosis cases (approximately 30%) in the stud-
ied material. However, it should be noted that in our
patients already total grading alone has correlated
with staging. Similarly to expression of p21, expres-
sion of Ki-67 also has correlated with grading and
liver steatosis. This suggests that HCV infection at
this stage on one hand induces augmented prolifera-
tion of hepatocytes and, on the other, increases
expression of p21, which is supposed to protect the
cell by inhibition of cell cycle and preventing against
neoplastic transformation. 
On the basis of the positive correlation between
expressions of p21 and cyclin D1 in our material we
can suggest that p21 represented rather a stimulator of
cyclin/CDK complex formation than it inhibited activ-
ity of the complexes. It has even been demonstrated
that expression of cyclin D1 induced transcription of
p21, which did not block the cell cycle but rather sta-
bilised the cyclin D/cdk4 complex [39]. The positive
correlation between p21 and cyclin D1 is consistent
with reports showing that p21 assists in securing
nuclear localization and acts as an assembly factor for
cyclin D/cdk complexes [40]. Expression of cyclin D1
is observed in several tumours in humans, but contra-
dictions are noted as to its prognostic importance
[41,42]. In HCC overexpression of cyclin D1 was
associated with a well-differentiated histology and a
low Ki-67 labeling index and may be an early event in
hepatocarcinogenesis [41]. Other studies showed that
overexpression of the cyclin D1 gene resulted in the
rapid growth of a subset of HCC [42]. Our results in
patients with CH-C have documented a very low
expression of cyclin D1 (below 5%), a higher one in
patients with HCC (10%) but the differences have not
been significant.
Our studies on expression of p53 have confirmed
mostly nuclear localization of the protein. We assume
that the positive expression of p53 provides an evi-
dence for presence of a protein form with a higher
half-life, which may result from mutation of p53 [43],
or from action of agents damaging DNA of host cells
with no detectable mutations of the protein [44]. Our
earlier observations confirmed presence of point muta-
tions in p53 in 2/14 examined livers of CH-C patients
[31]. 
In our material we have observed no correlations
between expression of cell-cycle proteins on one hand
and duration of HCV infection, level of HCV RNA,
serum and/or tissue concentration of AFP on the other. 
In summary, our present studies have demonstrated
mostly cytoplasmic expression of HCV proteins.
Expression of NS3 protein has prevailed in CH-C
patients. In the group of patients overexpression of p21
protein was detected, as compared to normal liver and
HCC. Positive correlations were disclosed between
expression of p21 in CH-C on one hand and patient's
age, grading, and steatosis on the other. Moreover,
expression of p21 was significantly correlated with
expressions of p53, cyclin D1 and Ki-67. A direct rela-
tionship was shown for expression of p21 and that of
NS3 proteins. 
Our results indicate that, upon partially preserved
potential for liver regeneration, elevated expression of
p53-dependent expression of p21 provides evidence
for inhibition of cell cycle in numerous hepatocytes,
which probably has a protective significance for
chronically injured or older hepatocytes. Out of the
examined HCV proteins, only NS3 seems to affect
control of p21 protein expression in a long-term in vivo
infection. Nevertheless, the current studies indicate
that neither expression of p21 protein nor that of viral
NS3 protein can serve as a marker of progression of
chronic hepatitis C to HCC in vivo. Definition of accu-
rate relationships between NS3 protein and cell cycle
control in in vivo conditions requires further studies.
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